Alipto
(3R,5R)-7-[2-(4-Fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
Drag to rotate; arrow keys step through the atoms. Structure from PubChem CID 60823.
Registration
- Applicants
- 1
- Registrations
- 4
Applicants and registrations
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Alipto 10 EACH TABLET CONTAINS ATORVASTATIN 10,0 mg | 10/ 20/ 40/ 80mgFilm-coated tablets | 48120648/7.5/1206Approved 21 June 2024 | Registered | Not determined | PIPIL |
| Alipto 20 EACH TABLET CONTAINS ATORVASTATIN 20,0 mg | 10/ 20/ 40/ 80mgFilm-coated tablets | 48120748/7.5/1207Approved 21 June 2024 | Registered | Not determined | PIPIL |
| Alipto 40 EACH TABLET CONTAINS ATORVASTATIN 40,0 mg | 10/ 20/ 40/ 80mgFilm-coated tablets | 48120848/7.5/1208Approved 21 June 2024 | Registered | Not determined | PIPIL |
| Alipto 80 EACH TABLET CONTAINS ATORVASTATIN 80,0 mg | 10/ 20/ 40/ 80mgFilm-coated tablets | 48120948/7.5/1209Approved 21 June 2024 | Registered | Not determined | PIPIL |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Atorvastatin
Consolidated Schedules 06 July 2026, line 5376
S4: Ezetimibe
Consolidated Schedules 06 July 2026, line 6302
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Background
SAHPRA documents
These documents come from SAHPRA's PI-PIL repository unless the line under a document says otherwise. Always consult with a healthcare professional for medical advice.